Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Mass Spec Software

By Drug Discovery Trends Editor | May 27, 2010

metquestThermo Fisher Scientific Inc., the world leader in serving science, introduced Thermo Scientific MetQuest, its software solution that enables laboratories to take full advantage of powerful Thermo Scientific Orbitrap mass spectrometry (MS) high-resolution accurate-mass (HRAM) full-scan data to perform quantitative metabolic stability studies and identify putative metabolites in a single injection. MetQuest software is designed to provide researchers performing drug metabolism and pharmacokinetic (DMPK) studies a significant time and cost savings when compared to traditional multiple reaction monitoring (MRM) methods. MetQuest software will be demonstrated at the Salt Palace Convention Center Salons 250BCEF, May 24 – May 26, 2010 during the  ASMS Conference on Mass Spectrometry and Allied Topics in Salt Lake City, Utah.

In combination with the industry-proven Thermo Scientific LTQ Orbitrap or Exactive families of liquid chromatography/mass spectrometry (LC/MS) systems, MetQuest software enables researchers to routinely perform quantitative and qualitative analyses in the same run. This solution is designed to offer substantial time and cost savings compared to triple quadrupole MRM approaches for metabolic studies. Publications from Zhang et al and Bateman et al report that quantitative results, including precision, accuracy, linearity and sensitivity for parent drugs and their metabolites, are comparable to those for established triple quadrupole MRM methods.   

“Obtaining both quantitative and qualitative information more effectively and earlier in the discovery process is paramount for the pharmaceutical industry,” said Patrick Bennett, director of marketing for scientific instruments at Thermo Fisher Scientific. “MetQuest software allows users to quantify and identify compounds and their metabolites simultaneously, and interrogate data later for additional information without having to re-run the entire experiment, which typically includes sample preparation and LC/MS analysis. This turn-key solution offers significant benefits to the industry and will revolutionize the way LC/MS experiments are performed in DMPK labs.” 

Understanding and documenting the metabolism of drug candidates is a key step in early-stage drug discovery. Traditionally, triple quadrupole systems using MRM methods have been used for compound quantitation. While the specificity of MRM is a key strength of these systems, it is also a limitation. MRM methods are effective in detecting a particular compound, but information about other components present in the sample, e.g. metabolites, may not be captured unless an MRM method is pre-defined to detect them.  It also requires time-consuming selection and optimization of MRM parameters, such as precursor ions, product ions, declustering and collision energies, for each target analyte of interest. The time, effort and skill level required is significant for laboratories that must analyze many new chemical entities every day.

The patented Orbitrap technology is ideal for compound identification and high-throughput screening for simultaneous qualitative and quantitative analyses. Its ultra-high mass resolution up to 100,000 filters out chemical noise such as isobaric interferences from biological matrices, enabling low detection limits and fewer false positives. The patents-pending processing methods in MetQuest software have been specifically developed to automatically process full-scan high resolution data for compound identification from even the most complex biological matrices without the need for pre-defined mass-to-charge values.  Because MetQuest software does not require time-consuming MS/MS method development and optimization, acquisition methods are more simple to set up and a single method can be used for multiple compounds. The automated generation of metabolic stability plots from the processed data saves time compared to manual generation of plots using other software. 

Date: May 24, 2010
Source: Thermo Fisher Scientific Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50